Lala, Mallika

A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation

Lala, M., Li, T. R., de Alwis, D. P., Sinha, V., Mayawala, K., Yamamoto, N., Siu, L. L., Chartash, E., Aboshady, H., & Jain, L. (2020) · European Journal of Cancer

Cancer Immunotherapy and BiomarkersPharmaceutical studies and practices

Cited by 165

Immunogenicity of pembrolizumab in patients with advanced tumors

van Vugt, M. J. H., Stone, J. A., De Greef, “. H. J. M. M., Snyder, E. S., Lipka, L., Turner, D. C., Chain, A., Lala, M., Li, M., Robey, S. H., et al. (2019) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersBiosimilars and Bioanalytical Methods

Cited by 57

Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial

Felip, E., Rojas, C. I., Schenker, M., Kowalski, D. M., Casarini, I. A., Csöszi, T., Şendur, M. A. N., Martins, J., Calles Blanco, A., Wang, C.-C., et al. (2025) · Annals of Oncology

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 40

Abstract CT036: Bioavailability of MK-3475A (pembrolizumab with berahyaluronidase alfa; “subcutaneous pembrolizumab”) in participants with advanced or metastatic solid tumors

Torras, O. R., Cohen, G., Cho, B. C., Rojas, C., Walton, C., Medina, L., Khanyile, R., Papai, Z., Lala, M., Song, G., et al. (2025) · Cancer Research

Cancer Immunotherapy and BiomarkersBiosimilars and Bioanalytical Methods

Cited by 3

Abstract CT035: Pharmacokinetics (PK), safety, and tolerability of pembrolizumab with berahyaluronidase alfa administered subcutaneously Q3W in participants with advanced melanoma

Coetzee, C., Khanyile, R., Cohen, G., McAdam, G., Walton, C., Chan, S. W., Rapoport, B., Caglevic, C., Yañez, P., Lala, M., et al. (2025) · Cancer Research

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 2